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Abstract Canine and porcine cerebrospinal fluid (CSF) were 
fractionated by size exclusion chromatography and analysed by a 
luminescence enzyme linked immunosorbent assay (ELISA) 
configured to detect P-amyloid. A peak of activity was observed 
in the CSF consistent with the molecular weight of P-amyloid. 
When CSF contaminated with blood was analysed an additional 
peak of immunoreactivity at a higher molecular weight was 
observed. The peak of activity was found to be derived from 
cross-reactivity of the immunoglobulins employed in the ELISA 
with haemoglobin. These findings are discussed with reference to 
primary and structural sequence homology between P-amyloid 
and haemoglobin from a number of species, the known properties 
of P-amyloid and recent clinical reports. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Alzheimers disease is the most common form of adult onset 
dementia. Approximately 5-10% of individuals in their 60s 
and more than 20% in their 80s show the symptoms of 
what is currently neither a curable or preventable disease 
[1]. The pathology of Alzheimer's disease is characterised by 
neuronal dysfunction and deposition of amyloid A4 protein 
(P-amyloid) as extracellular plaques and cerebrovascular amy-
loid [2]. 
P-Amyloid is a self-aggregating peptide which consists of 
39-43 amino acids [3]. It is formed by cleavage of amyloid 
precursor protein (APP), a glycosylated receptor-like integral 
membrane protein, by two unidentified enzymes called tenta-
tively P- and y-secretase [4]. 
An ELISA has been configured in our laboratories compris-
ing two monoclonal antibodies raised to different epitopes on 
P-amyloid. The two antibodies, named 2F12 and 1E8, recog-
nise the epitope from amino acid residues 4-7 , ( F R H D ) and 
18-22, (VFFAE) respectively. P-amyloid-like immunoreactiv-
ity has been identified in the CSF of a number of species at 
ng-ml - 1 concentrations [5]; however, little data exist to sup-
port the expectation that the ELISA specifically recognises 
p-amyloid protein. 
2. Materials and methods 
2.1. Fractionation of CSF and brain samples by low-pressure 
size-exclusion chromatography 
CSF was fractionated by size exclusion using a calibrated Superdex 
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75 (Pharmacia, St. Albans, UK) column (16x750 mm) in 50 mM 
Tris-HCl (pH 8.0)+125 mM NaCl at 0.5 ml-min-1. A sample of syn-
thetic (3-amyloid 1^40 (Bachem, Saffron Waldon, UK) showed a peak 
with an apparent molecular weight of 5 kDa which is in good agree-
ment with the expected value (4329 Da). 
2.2. HPLC size-exclusion chromatography of synthetic amyloid 
Synthetic p-amyloid 1^40 (Bachem, Saffron Waldon, UK) was 
chromatographed using a calibrated TSK3000GW (Anachem, Luton, 
UK) column (4.6X300 mm) in 50 mM Tris-HCl (pH 8.0) + 125 mM 
NaCl at 0.5 ml-min-1. Synthetic (3-amyloid 1-40 125I-labelled at the 
lysine residue 16 (Penninsula Labs, St. Helens, UK) was added to the 
unlabelled synthetic P-amyloid 1^40 (Bachem, Saffron Waldon, UK) 
and mixed at a molar ratio of 1:1 with dog haemoglobin prior to 
incubation at ambient temperature for 24 h. Radioactivity was deter-
mined off-line using a gamma-counter (Wallac, Milton Keynes, UK). 
2.3. $A4 ELISA 
A Dynex Micolite II microtitre plate (Dynex Technologies, Billings-
hurst, UK), was coated overnight at 4°C with 1E8 monoclonal anti-
body (4 ug-mr1) in PBS. The plate was blocked with 20% (w/v) fish 
gelatin (Amersham International, Little Chalfont, UK), 1.25 ml of 
goat serum (Sigma, Poole, UK) in 50 ml assay buffer (50 mM Tris-
HCl (pH 7.4) + 0.0005% (v/v) Tween-20 + 2.18 M NaCl + 1.25 g 
bovine y-globulins (Sigma, Poole, UK)) for 60 min at 37°C. pA4(l-40) 
(Bachem, Saffron Waldon, UK) standards were made up in assay 
buffer to give a final concentration range of 1.25-80 ng-ml-1. Fifty 
microlitres of CSF samples or standards were incubated with 50 ul of 
4 ug-ml-1 of biotinylated 2F12 (Fab fragments) in assay buffer for 
90 min at 37°C. After washing the samples were incubated with a 
1:2000 dilution streptavidin/biotinylated horseradish peroxidase com-
plex (Amersham International, Little Chalfont, UK), at 37°C for 
60 min in assay buffer. Visualisation was by luminescence, generated 
by the addition of an immunoassay reagent kit containing luminol 
plus enhancer (Amersham International, Little Chalfont, UK), and 
quantified on a Dynatech luminometer (ML3000, Dynex Technolo-
gies, Billingshurst, UK). For the haemoglobin experiments, 50 ul of 
haemoglobin, final concentrations of 0-5 mg-ml-1 (Sigma, Poole, UK) 
from various species, was added concomitantly to the wells with 50 ul 
of 2F12 (4 ug-ml-1). Subsequent assay steps were as described above. 
All plate washings were with PBS + 0.05% (v/v) Tween-20 (Sigma, 
Poole, UK). 
2.4. SDS-PAGEIblotting 
10% (w/v) polyacrylamide gels were loaded and run with 20 u.g 
protein per track and either visualised by silver stain or electroblotted. 
Gels were blotted onto PVDF membrane using a Tris/glycine transfer 
buffer (Kodak, Hemel Hempstead, UK) for 2 h at constant current 
80 mA. For N-terminal sequencing, blots were stained with 0.2% (w/v) 
Amido Black and destained in water. For immunoblotting the blot 
was blocked for 1 h in Tris-buffered saline (TBS, pH 7.4) + 5% (w/v) 
bovine serum albumin (BSA) (Promega, Southampton, UK), washed 
in TBS + 0.5% (v/v) Tween-20 and incubated overnight with a poly-
clonal antibody to p-amyloid (B2) in TBS + 0.05% (v/v) Tween-20 + 
2% (w/v) BSA. Following washing the blot was incubated for 1 h with 
anti-rabbit IgG (1:6000) in TBS + 2% (w/v) BSA. The blot was 
washed and incubated with rabbit peroxidase anti-peroxidase (PAP) 
solution (1:4000 in TBS + 0.05% (v/v) Tween-20 + 2% (w/v) BSA). 
The blot was washed and incubated with diaminobenzidine (Vector, 
Peterborough, UK) to visualise the bands. 
For radioisotope studies 125l-labelled synthetic P-amyloid (Peninsu-
la Labs, St. Helens, UK) was introduced in the presence and absence 
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of dog haemoglobin and run on 4-20% (w/v) acrylamide gels (R&D 
Systems, Abingdon, UK) under native or reducing SDS-PAGE con-
ditions. Gels were stained with Coomassie Blue, dried under vacuum 
and analysed by both scanning laser densitometry and phosphoim-
agery (Molecular Dynamics, Chesham, UK). 
2.5. Reverse-phase HPLC 
Samples were analysed on a Hewlett Packard 1090L (Stockport, 
UK) by reverse-phase HPLC using 25 ul of injection onto an Aqua-
pore RP-300, C8, 7 urn (220X2.1 mm) column at 200 ixl-min"
1 (40°C). 
A gradient elution from 0.1% (v/v) TFA to 0.1% TFA + 70% (v/v) 
acetonitrile equivalent to a 1%-min-1 linear increase of acetonitrile 
was used. Detection was by UV at 214 nm. 
2.6. N-terminal sequencing 
Collected peptide peaks and blots were sequenced using an auto-
mated ABI 477A Pulsed Liquid Sequencer (Warrington, UK) with on-
line 120A PTH-AA Analyser. Peptide solution (30 u.1) was pipetted on 
to a cleaned glass-fibre disc, dried under nitrogen and sequenced using 
FAST-1 cycle conditions. Blots were sequenced using BLOTT-2 
cycles. Derivatised amino acids were chromatographed using a PTH 
Cis, 5 urn (220X2.1 mm) column using a gradient elution from 0 to 
90% acetonitrile in 3.5% (v/v) THF at 250 ul-min-1. 
3. Results and discussion 
Pig CSF (5 ml) was separated by size-exclusion chromatog-
raphy on a Superdex 75 column. Immunoreactivity profiles of 
fractions from the ELISA assay indicated two peaks of activ-
ity (Fig. 1). The later eluting of the two peaks represented 
activity at the expected molecular weight of P-amyloid 
(4 kDa). Fractions from the high molecular weight species 
recognised by the ELISA were separated in duplicate by 
SDS-PAGE and electroblotted on to PVDF membrane. These 
were either stained for total protein or probed with an anti-
body raised to (3-amyloid. Bands from the total protein stain 
which corresponded to apparent (3-amyloid immunoreactivity 
at 16 kDa in the Western blot were sequenced by automated 
Edman Chemistry. Two major sequences indicated the pres-
ence of pig haemoglobin a- and P-chains. 
When dog CSF was fractionated on the Superdex column, a 
peak of immunoreactivity was observed at the expected mo-
lecular weight for (3-amyloid. A second higher molecular 
weight peak of immunoreactivity analogous with the pig 
CSF was observed. The lower molecular weight peak was 
collected and further analysed by reverse-phase HPLC. A 
peak of immunoreactivity of similar retention time to syn-
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Fig. 1. ELISA analysis of pig CSF gel filtration samples. 
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Fig. 2. SDS-PAGE of clean and contaminated dog CSF. 
thetic (3-amyloid standard was observed; however, the levels 
were below the level of detection of automated N-terminal 
sequencing even when an equivalent to 30 ml of CSF was 
processed. When a sample of dog CSF was specifically col-
lected avoiding blood-derived contamination only one peak of 
immunoreactivity was identified with an apparent molecular 
weight of approximately 4 kDa. Possible explanations for the 
immunoreactivity of the higher molecular weight peak in-
cluded P-amyloid aggregates, p-amyloid in association with 
another protein, a larger fragment of APP and/or antibody 
cross-reactivity with other proteins. 
Samples of clean and blood-contaminated dog CSF were 
analysed by SDS-PAGE under reducing conditions and silver 
staining (Fig. 2). Two major bands were observed with ap-
parent molecular weights of 67 and 15 kDa. In the case of the 
contaminated sample an increase in the 15 kDa band was 
noted. In the uncontaminated canine CSF the major sequence 
at 15 kDa (VPAGTDGPN) showed 33% sequence identity 
with the N-terminal sequence of human transthyretin. It is 
noteworthy that the sequence for canine transthyretin is cur-
rently unavailable in the public sequence databases. In the 
contaminated dog CSF two additional sequences were iden-
tified as the a- and P-chains of dog haemoglobin which 
have a subunit molecular weight of 15217 Da (a-chain) and 
15 996 Da (P-chain). 
It was considered feasible that interactions between amyloid 
and haemoglobin in vivo may occur. To investigate this 
p-amyloid was spiked with 125I-labelled P-amyloid and the 
retention of radioactivity in the presence of dog haemoglobin 
monitored using size exclusion HPLC (not shown). Analysis 
of fractions indicated that a small amount of radioactivity 
(<10%) was associated with the haemoglobin. However, 
this binding was non-saturable and could not be competed 
out by unlabelled P-amyloid in a 1000 molar excess suggesting 
non-specific interaction. Binding with similar characteristics 
was observed with bovine serum albumin. Analysis by native 
PAGE and SDS-PAGE followed by phosphorimagery indi-
cated that in the presence of haemoglobin an additional minor 
band of radioactivity in native format was observed, but was 
not stable to SDS (Fig. 3). This was in contrast to the ap-
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Fig. 3. Native and SDS-PAGE analysis of canine haemoglobin in the presence and absence of 125I-labelled B-amyloid 1^0. Native PAGE gels 
are shown in Coomassie stain (a) and phosphoimage (b). The observed extra band in the haemaglobin plus P-amyloid band is denoted by the 
arrow (-»). Reducing SDS-PAGE gels are shown in Coomassie stain (c) and phosphoimage (d). 
parent immunoreactivity which as described earlier was stable 
to reducing SDS-PAGE as visualised by Western blotting. 
Reports exist that transthyretin (pre-albumin) found in the 
C S F plays a role in amyloidogenesis with a constantly grow-
ing list of single point mutat ions of transthyretin resulting in 
familial amyloidosis [6-8]. Da ta described earlier indicated the 
presence of transthyretin in both clean and contaminated dog 
C S F (Fig. 2). On separation of both clean and contaminated 
canine CSF by RP-HPLC, peaks were noted in the contami-
nated CSF with sequences showing 60% and 64% identity 
with human transthyretin. Although transthyretin has been 
identified in CSF samples, the lack of P-amyloid immunoreac-
tivity in the uncontaminated sample (containing transthyretin) 
suggests that transthyretin is not responsible for the observed 
reactivity. A possible explanation for failure to determine any 
complexation of amyloid-transthyretin may be that amyloid 
associated with transthyretin is sterically hindered from being 
detected in the immunoassay. 
Table 1 
Sequence homology between B-amyloid epitopes and haemoglobin (Hb) from human, bovine and dog. Identity and similarity are defined in the 
text 
Epitope Species Chain Sequence % Identity % Similarity 
2F12 
(1-16) 
1E8 
(13-27) 
Human Hb 
D o g H b 
Bovine Hb 
Human Hb 
D o g H b 
Bovine Hb 
a 
P 
a 
P 
a 
P 
a 
P 
a 
P 
a 
P 
47 D _ 60 K 
76A_ 9 5 K 
4 7 D _ 60 K 
112C_ 125Q 
77 G _ 92 R 
79 D _ 94 K 
W3 J J _ 116JJ 
99 D _ 112C 
15 D _ 27E 
9 9 D _ H 2 C 
W3 Yf_ 116j) 
110y_120£ 
28.6 
33.3 
21.4 
28.6 
12.5 
25.0 
28.5 
0 
30.8 
0 
35.7 
27.3 
57.1 
60.0 
50.0 
35.7 
37.5 
37.5 
50.0 
57.1 
69.2 
57.1 
57.1 
63.6 
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Fig. 4. Haemoglobin immunoreactivity in p-amyloid ELISA. 
Apolipoprotein E (ApoE) may be involved in amyloid 
transport [9]. ApoE has been identified in association with 
amyloid in plaque formations and there is evidence of the 
epsilon 4 allele of ApoE as a risk factor for familial Alzhei-
mer's disease [10-12]. No evidence was found to support the 
association between endogenous ApoE and amyloid in this 
study. The bands of immunoreactivity observed, when prob-
ing the immunoblot with antibodies raised against P-amyloid, 
corresponded with both the presence of haemoglobin ( = 1 5 
kDa) as determined by sequencing and a lower band at the 
expected molecular weight of amyloid ( = 4 kDa). No band 
immunoreactive with anti-P-amyloid corresponded with bands 
highlighted when probing with antibodies raised against 
ApoE. The lack of detectable ApoE-amyloid complex is not 
unexpected as the published levels of complex are low even in 
the presence of excess P-amyloid [11]. 
To test the hypothesis that the antibodies 1E8 and 2F12 
recognise haemoglobin, samples of haemoglobin (Sigma, 
Poole, UK) from various species was assayed by ELISA 
(Fig. 4). There was an apparent cross-reactivity of the anti-
bodies used in the amyloid ELISA with haemoglobin at levels 
> 1 mg-ml-1; however, the cross-reactivity is species depend-
ent with the order of reactivity canine > human > porcine > 
ovine > bovine. 
The antibodies used in the assay, 1E8 and 2F12, were raised 
against the P-amyloid derived peptides 13H-27N and 1D-16K, 
respectively. The epitopes were later mapped to 18V-22E (1E8) 
and 4F- 7D (2F12). Primary sequence homology was com-
pared between the peptide immunogen sequences and haemo-
globin a- and P-chains from various species. Using BestFit 
comparison on the GCG protein sequence analysis software 
(Genetic Computer Group, Madison, USA), the identity var-
ied widely from 0% to 35.7% depending on the haemoglobin 
species and subunit, whereas the similarity as defined by the 
Smith Waterman algorithm ranged from 35.7% to 69.2% (Ta-
ble 1). These data therefore demonstrate a relatively low pri-
mary sequence homology between p-amyloid and mammalian 
haemoglobin. The epitope sequences recognised by the anti-
bodies were not present in the primary sequence of a- or 
P-haemoglobin chain of the three species. Consideration of 
the homology of the primary sequence of P-amyloid and hae-
moglobin is therefore not satisfactory to explain the apparent 
cross-reactivity observed. In addition primary sequence ho-
mology does not correlate well with the observed species dif-
ferences in cross-reactivity. 
The consideration and comparison of the primary sequence 
homology does not reflect the 3-dimensional spatial orienta-
tion of the amino acid residues in the haemoglobin tertiary 
structure. Experimental crystal structures do exist for both the 
bovine (lhda) and human (lhga) haemoglobin entities and the 
resolution of these structures is 2.2 A and 2.1 A, respectively. 
At present, there is no experimental structure for canine hae-
moglobin; however, the homology of this sequence with the 
bovine/human sequences is good and as such, the canine 
structure is predicted to have the same fold motifs as the other 
family members. The structures were overlaid (RMS 0.57 A, 
based on superimposition of the backbone atoms) and all the 
interatomic distances between the surface residues calculated. 
These distances were used to highlight several p-amyloid anti-
body epitope regions that are close in 3-dimensional space and 
that also occur on the surface of the haemoglobin structure. 
For example, the 2F12 epitope, FRHD, has an analogue in 
the haemoglobin structure, namely, 4 1F-4 0R-8 9H-8 5D, these 
residues are both surface accessible and occur in close prox-
imity to each other. Clearly these relationships are only ap-
parent upon consideration of the actual 3-dimensional struc-
ture and cannot be derived solely from the primary sequence 
information. Similar binding regions exist for the 1E8 anti-
body epitope, 98V-42F-45F-62A-21E. Indeed, basing the anal-
ysis solely on the binding regions, the P-amyloid antibodies 
have molecular recognition sites on the haemoglobin structure 
that are close in space; however, no inter-species differences 
are predicted. But assuming that the canine sequence has the 
same overall fold as the other haemoglobins, then 82A, which 
exists in both canine and human, is changed to 82E in bovine 
haemoglobin. This changed site is close in space to the 2F12 
binding site reported earlier and it is not unreasonable that 
such a significant surface amino acid point mutation could 
have a major effect on the preferential binding of the anti-
body. 
It should also be noted that the limit of detection for 
P-amyloid (ng-ml-1) compared to that for haemoglobin 
(mg-rnl-1) indicates a 106 fold selectivity for P-amyloid. It is 
apparent that the relatively high concentration of haemoglo-
bin in the circulatory system (14 g-dl-1 in human blood) en-
sures that even low levels of contamination in the CSF due to 
traumatic tap or cerebral bleeding can have a significant im-
pact on the bioassay of P-amyloid. 
These data support the view that the immunoreactivity is 
the result of genuine cross-reactivity between P-amyloid and 
haemoglobin and has direct relevance for ex vivo measure-
ment of P-amyloid in the presence of relatively low levels of 
haemoglobin. Such cross-reactivities are not without prece-
dent. Human p-amyloid peptide has been shown to display 
cross-reactivity with human glyceraldehyde-3-phosphate dehy-
drogenase [13] and rat amyloid with rat calcitonin gene-re-
lated peptide [14], despite displaying only 19% and 17% pri-
mary sequence identity, respectively. 
The apparent cross-reactivity between P-amyloid and hae-
moglobin has clear implications for the detection and quanti-
tation of P-amyloid in biological tissues and fluids. Although 
the potential clinical relevance of such observations is less 
clear some reports have postulated a link between haemoglo-
bin and Alzheimer's disease. 
Increased levels of haemoglobin-derived peptides have been 
reported in the brain tissue of Alzhemier patients [15]. Of 
several hundred peaks analysed by RP-HPLC, 15 peaks 
were elevated in Alzheimer's patients. Of these, 9 peaks 
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were found to be fragments of haemoglobin. Entry of haemo-
globin-derived peptides into the CNS may be a manifestation 
of a loss of blood-brain barrier integrity [16,17]. It appears 
that oxidative stress may have a role to play in the pathology 
of Alzheimer's disease. An elevated activity of the inducible 
form of haem-oxygenase-1, catalysing the conversion of the 
pro-oxidant haem to biliverdin which is ultimately converted 
to the anti-oxidant bilirubin has been observed in Alzheimer's 
disease [18,19]. Further work will be needed to fully elucidate 
the role of haemoglobin in Alzheimer pathology. 
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